Leap Therapeutics, Inc. (LPTX)

Oncology Corporate Profile

Stock Performance


HQ Location

47 Thorndike St, Suite B1-1
Boston, MA 2141

Company Description

Leap Therapeutics was founded on the principle that investing in great science and targeted research will rapidly translate molecules into high impact therapeutics. Our pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology. Led by a proven management team, Leap Therapeutics is dedicated to building and developing a pipeline of therapeutics that has the potential to change the practice of cancer medicine.

Website: https://www.leaptx.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
DKN-01anti-DKK1 antibodyCholangiocarcinomaI
DKN-01anti-DKK1 antibodyEsophageal cancerI
DKN-01anti-DKK1 antibodyNon Small Cell Lung Cancer (NSCLC)I
TRX518anti-GITR antibodyVarious cancer typesI
DKN-01 (+ pembrolizumab)anti-DKK1 antibodyEsophageal cancerPreclinicalMerck

Source: https://www.leaptx.com/

Recent News Headlines

There are no news items to display